methylnaltrexone bromide · Salix Pharms · NDA 021964, 208271

Relistor

Earliest generic entry, as listed · earliest of 4 marketed strengths
31 Dec 2030

Other strengths are listed to 10 Mar 2031.

Blocked by patent: US 8247425. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 12 unexpired

13 Orange Book listing rows for 12 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 10307417drug product10 Mar 2031
US 10376505drug product10 Mar 2031
US 8524276drug product10 Mar 2031
US 8956651drug product10 Mar 2031
US 9314461drug product10 Mar 2031
US 8247425use U-1185 · sets the listed date31 Dec 2030
US 8420663use U-118530 Sep 2029
US 8822490drug product, use U-118530 Sep 2029
US 9180125drug product, use U-118530 Sep 2029
US 9492445drug product, use U-118530 Sep 2029
US 9724343drug product, use U-118530 Sep 2029
US 12303592drug product, use U-4197, U-41983 Aug 2027
US 12303592 listing rowdrug product, use U-41973 Aug 2027
US 12303592 listing rowdrug product, use U-41983 Aug 2027

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 4

NDA · productFormStrengthListed expiry
021964 · 001 · RLDsolution, subcutaneous12MG/0.6ML (12MG/0.6ML)31 Dec 2030
021964 · 002 · RLDsolution, subcutaneous8MG/0.4ML (8MG/0.4ML)31 Dec 2030
021964 · 003 · RLDsolution, subcutaneous12MG/0.6ML (12MG/0.6ML)31 Dec 2030
208271 · 001 · RLDtablet, oral150MG10 Mar 2031